Protara Therapeutics, Inc. (NASDAQ:TARA) Shares Bought by Assenagon Asset Management S.A.

Posted by Defense World Staff on Oct 21st, 2023

Assenagon Asset Management S.A. raised its stake in Protara Therapeutics, Inc. (NASDAQ:TARA – Free Report) by 67.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 29,051 shares of the company’s stock after buying an additional 11,715 shares during the quarter. Assenagon Asset Management S.A. owned about 0.26% of Protara Therapeutics worth $69,000 at the end of the most recent quarter.

Separately, Virtu Financial LLC acquired a new position in Protara Therapeutics in the second quarter valued at about $30,000. 46.44% of the stock is owned by hedge funds and other institutional investors.

Protara Therapeutics Price Performance

Shares of NASDAQ:TARA opened at $1.40 on Friday. The firm has a market capitalization of $15.86 million, a PE ratio of -0.24 and a beta of 1.14. The firm’s 50-day moving average is $1.94 and its two-hundred day moving average is $2.53. Protara Therapeutics, Inc. has a 1 year low of $1.39 and a 1 year high of $4.18.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last issued its quarterly earnings results on Thursday, August 3rd. The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.03). Analysts expect that Protara Therapeutics, Inc. will post -3.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $23.00 target price on shares of Protara Therapeutics in a research report on Friday, August 4th.

Read Our Latest Report on Protara Therapeutics

Protara Therapeutics Profile

(Free Report)

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.